Ceftobiprole: A new cephalosporin for the treatment of skin and skin structure infections

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 7, 2009, Pages 777-791

  Schirmer, Patricia L ^a,b   Deresinski, Stanley C ^b,c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

^c SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

Antimicrobial; Ceftobiprole; Cephalosporin; Complicated skin and skin structure infection; cSSSI; Efficacy; Gram negative; Gram positive; Methicillin resistant Staphylococcus aureus; MRSA; Safety; Staphylococcus aureus

Indexed keywords

AMPICILLIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTOBIPROLE; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; LINEZOLID; METRONIDAZOLE; MINOCYCLINE; ORITAVANCIN; PLACEBO; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN; ZEFTERA; ZEVTERA;

ABSCESS; ANAPHYLAXIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL MENINGITIS; CELLULITIS; CLINICAL TRIAL; CONSTIPATION; DIABETIC FOOT; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; GASTROINTESTINAL DISEASE; HUMAN; INJECTION SITE REACTION; INSOMNIA; KIDNEY DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MYOSITIS; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; OSTEOMYELITIS; PERITONITIS; PHARMACODYNAMICS; PRURITUS; PSEUDOMONAS INFECTION; REVIEW; SEPTICEMIA; SINGLE DRUG DOSE; SKIN ALLERGY; SKIN AND SKIN STRUCTURE INFECTION; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TASTE DISORDER; URTICARIA; VOMITING; WOUND INFECTION;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CLINICAL TRIALS, PHASE III AS TOPIC; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MULTICENTER STUDIES AS TOPIC; SKIN DISEASES, BACTERIAL; TREATMENT OUTCOME;

EID: 70350686593     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.54     Document Type: Review

References (122)

1. DiNubile MJ, Lipsky BA. Complicated infections of skin and skin structures: when the infection is more than skin deep. J. Antimicrob. Chemother. 53(Suppl. 2), ii37-ii50 (2004).
2. Lipsky BA, Weigelt JA, Gupta V, Killian A, Peng MM. Skin, soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes. Infect. Control Hosp. Epidemiol. 28(11), 1290-1298 (2007). (Pubitemid 47596568)
3. Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg. Infect. (Larchmt) 6(3), 283-295 (2005).
4. Nichols RL. Optimal treatment of complicated skin and skin structure infections. J. Antimicrob. Chemother. 44(Suppl. A), 19-23 (1999).
5. Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn. Microbiol. Infect. Dis. 57(1), 7-13 (2007).
6. Barbour A, Schmidt S, Rand KH, Derendorf H. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents 34(1), 1-7 (2009). •• Excellent review of ceftobiprole.
7. Bell J, Turnidge J. SENTRY Antimicrobial Surveillance Program Asia-Pacific region and South Africa. Commun. Dis. Intell. 27(Suppl.), S61-S66 (2003).
8. Biedenbach D, Bell J, Sader H, Fritsche T, Jones R, Turnidge J. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004). Int. J. Antimicrob. Agents 30(2), 143-149 (2007). (Pubitemid 46977187)
9. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control. 32(8), 470-485 (2004).
10. Deresinski SC. Ceftobiprole: breaking therapeutic dogmas of the β-lactam class. Diagn. Microbiol. Infect. Dis. 61(1), 82-85 (2008).
11. Palavecino E. Community-acquired methicillin-resistant Staphylococcus aureus infections. Clin. Lab. Med. 24(2), 403-418 (2004). (Pubitemid 38737259)
12. Olesevich M, Kennedy A. Emergence of community-acquired methicillin-resistant Staphylococcus aureus soft tissue infections. J. Pediatr. Surg. 42(5), 765-768 (2007). (Pubitemid 46719205)
13. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 46(Suppl. 5), S368-S377 (2008).
14. Styers D, Sheehan DJ, Hogan P, Sahm DF. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann. Clin. Microbiol. Antimicrob. 5, 2 (2006).
15. Miller LG, Perdreau-Remington F, Bayer AS et al. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin- susceptible S. aureus infection: a prospective investigation. Clin. Infect. Dis. 44(4), 471-482 (2007).
16. Daum RS. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N. Engl. J. Med. 357(4), 380-390 (2007).
17. Frazee BW, Lynn J, Charlebois ED, Lambert L, Lowery D, Perdreau-Remington F. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann. Emerg. Med. 45(3), 311-320 (2005). (Pubitemid 40261163)
18. Moran GJ, Krishnadasan A, Gorwitz RJ et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355(7), 666-674 (2006). (Pubitemid 44244537)
19. Davis SL, Perri MB, Donabedian SM et al. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J. Clin. Microbiol. 45(6), 1705-1711 (2007).
20. Rennie RP, Jones RN, Mutnick AH. Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn. Microbiol. Infect. Dis. 45(4), 287-293 (2003).
21. Artigas V, Serra J, Calabuig R, Garcia P, Allende L, Rius X. Perineal necrotizing infection. Curr. Surg. 47(1), 4-7 (1990).
22. Cabrera H, Skoczdopole L, Marini M, Della Giovanna P, Saponaro A, Echeverria C. Necrotizing gangrene of the genitalia and perineum. Int. J. Dermatol. 41(12), 847-851 (2002).
23. Taviloglu K, Cabioglu N, Cagatay A et al. Idiopathic necrotizing fasciitis: risk factors and strategies for management. Am. Surg. 71(4), 315-320 (2005). (Pubitemid 43073479)
24. Principles and Practice of Infectious Diseases (6th Edition). Mandell GL, Bennett JE, Dolin R (Eds). Churchill-Livingstone, Elsevier, PA, USA (2005).
25. Rossolini GM. Redesigning β-lactams to combat resistance: summary and conclusions. Clin. Microbiol. Infect. 13(Suppl. 2), 30-33 (2007).
26. Ueda Y, Kanazawa K, Eguchi K, Takemoto K, Eriguchi Y, Sunagawa M. In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem. Antimicrob. Agents Chemother. 49(10), 4185-4196 (2005). (Pubitemid 41400963)
27. Deresinski SC. The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials. Diagn. Microbiol. Infect. Dis. 61(1), 103-109 (2008).
28. Micek ST. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 45(Suppl. 3), S184-S190 (2007).
29. Deresinski S. Vancomycin: does it still have a role as an antistaphylococcal agent? Expert Rev. Anti-Infect. Ther. 5(3), 393-401 (2007). (Pubitemid 47050161)
30. Deresinski S. Counterpoint: vancomycin and Staphylococcus aureus - an antibiotic enters obsolescence. Clin. Infect. Dis. 44(12), 1543-1548 (2007). (Pubitemid 46871499)
31. Golper TA, Schulman G, D'Agata EM. Indications for vancomycin in dialysis patients. Semin. Dial. 13(6), 389-392 (2000).
32. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol. 44(11), 3883-3886 (2006). (Pubitemid 44737223)
33. Appelbaum PC, Jacobs MR. Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. Curr. Opin. Microbiol. 8(5), 510-517 (2005).
34. Diekema DJ, Pfaller MA, Schmitz FJ et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32(Suppl. 2), S114-S132 (2001).
35. Murphy S, Pinney RJ. Teicoplanin or vancomycin in the treatment of gram-positive infections? J. Clin. Pharm. Ther. 20(1), 5-11 (1995).
36. Candiani G, Abbondi M, Borgonovi M, Romano G, Parenti F. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J. Antimicrob. Chemother. 44(2), 179-192 (1999). (Pubitemid 29389280)
37. Ament PW, Jamshed N, Horne JP. Linezolid: its role in the treatment of Gram-positive, drug-resistant bacterial infections. Am. Fam. Physician 65(4), 663-670 (2002). (Pubitemid 34175040)
38. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin. Infect. Dis. 38(7), 994-1000 (2004).
39. Manzella JP. Quinupristin-dalfopristin: a new antibiotic for severe Gram-positive infections. Am. Fam. Physician 64(11), 1863-1866 (2001).
40. Sader HS, Fritsche TR, Jones RN. Potency and bactericidal activity of iclaprim against recent clinical Gram-positive isolates. Antimicrob. Agents Chemother. 53(5), 2171-2175 (2009).
41. Schneider P, Hawser S, Islam K. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg. Med. Chem. Lett. 13(23), 4217-4221 (2003). (Pubitemid 37410316)
42. Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob. Agents Chemother. 47(1), 400-404 (2003). (Pubitemid 36070396)
43. Kanafani ZA, Corey GR. Ceftaroline: a cephalosporin with expanded Gram-positive activity. Future microbiol. 4, 25-33 (2009).
44. Kurazono M, Ida T, Yamada K et al. In vitro activities of ME1036 (CP5609), a novel parenteral carbapenem, against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 48(8), 2831-2837 (2004). (Pubitemid 38989143)
45. El-Shaboury SR, Saleh GA, Mohamed FA, Rageh AH. Analysis of cephalosporin antibiotics. J. Pharm. Biomed. Anal. 45(1), 1-19 (2007).
46. Anderson SD, Gums JG. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin. Ann. Pharmacother. 42(6), 806-816 (2008).
47. Murthy B, Schmitt-Hoffmann A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin. Pharmacokinet. 47(1), 21-33 (2008). •• Key article on the pharmacokinetics and pharmacodynamics of ceftobiprole.
48. Schmitt-Hoffmann A, Roos B, Schleimer M et al. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. 48(7), 2570-2575 (2004). • Phase I clinical trial for ceftobiprole. (Pubitemid 38823426)
49. Janssen-Ortho Inc., Zeftera Product Monograph. Toronto, Canada, July 2008.
50. Schmitt-Hoffmann A, Nyman L, Roos B et al. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. 48(7), 2576-2580 (2004). • Phase I clinical trial for ceftobiprole.
51. Livermore DM. Can β-lactams be re-engineered to beat MRSA? Clin. Microbiol. Infect. 12(Suppl. 2), 11-16 (2006).
52. Davies TA, Page MGP, Shang W, Andrew T, Kania M, Bush K. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51(7), 2621-2624 (2007). (Pubitemid 47047351)
53. Noel GJ. Clinical profile of ceftobiprole, a novel β-lactam antibiotic. Clin. Microbiol. Infect. 13(Suppl. 2), 25-29 (2007).
54. Davies TA, Shang W, Bush K. Activities of ceftobiprole and other β-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x. Antimicrob. Agents Chemother. 50(7), 2530-2532 (2006). (Pubitemid 43993197)
55. Hebeisen P, Heinze-Krauss I, Angehrn P, Hohl P, Page MG, Then RL. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45(3), 825-836 (2001). (Pubitemid 32182033)
56. Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788. Drugs in R D 7(5), 305-311 (2006).
57. Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broadspectrum cephalosporin. Antimicrob. Agents Chemother. 49(10), 4210-4219 (2005). (Pubitemid 41400966)
58. Bogdanovich T, Clark C, Ednie L et al. Activities of ceftobiprole, a novel broadspectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob. Agents Chemother. 50(6), 2050-2057 (2006). (Pubitemid 43807525)
59. Banerjee R, Gretes M, Basuino L, Strynadka N, Chambers HF. In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52(6), 2089-2096 (2008). (Pubitemid 351758546)
60. Queenan A, Shang W, Crespo-Carbone S, Baum EZ, Bush K. Mechanisms of ceftobiprole and ceftazidime resistance development in Gram-negative clinical isolates from cSSSI subjects. Presented at: 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington DC, USA, 25-28 October 2008
61. Baum EZ, Crespo-Carbone SM, Morrow BJ et al. Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53(7), 2785-2790 (2009).
62. Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J. Antimicrob. Chemother. 50(6), 915-932 (2002).
63. Mouton JW, Schmitt-Hoffmann A, Shapiro S, Nashed N, Punt NC. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob. Agents Chemother. 48(5), 1713-1718 (2004). (Pubitemid 38544379)
64. Leonard SN, Cheung CM, Rybak MJ. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52(8), 2974-2976 (2008).
65. Denis O, Deplano A, Nonhoff C et al. In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrob. Agents Chemother. 50(8), 2680-2685 (2006). (Pubitemid 44198687)
66. Wang H, Liu Y, Sun H, Xu Y, Xie X, Chen M. In vitro activity of ceftobiprole, linezolid, tigecycline, and 23 other antimicrobial agents against Staphylococcus aureus isolates in China. Diagn. Microbiol. Infect. Dis. 62(2), 226-229 (2008).
67. Yun HC, Ellis MW, Jorgensen JH. Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees. Diagn. Microbiol. Infect. Dis. 59(4), 463-466 (2007).
68. Fritsche TR, Sader HS, Jones RN. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Diagn. Microbiol. Infect. Dis. 61(1), 86-95 (2008).
69. Deshpande LM, Jones RN. Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Clin. Microbiol. Infect. 9(11), 1120-1124 (2003).
70. Deshpande L, Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates. Diagn. Microbiol. Infect. Dis. 50(1), 73-75 (2004). (Pubitemid 39360265)
71. Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49(3), 884-888 (2005).
72. Lin G, Appelbaum PC. Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill ana lysis. Diagn. Microbiol. Infect. Dis. 60(2), 233-235 (2008).
73. Bozdogan B, Esel D, Whitener C, Browne FA, Appelbaum PC. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. 52(5), 864-868 (2003). (Pubitemid 37407819)
74. Chung M, Antignac A, Kim C, Tomasz A. Comparative study of the susceptibilities of major epidemic clones of methicillin-resistant Staphylococcus aureus to oxacillin and to the new broad-spectrum cephalosporin ceftobiprole. Antimicrob. Agents Chemother. 52(8), 2709-2717 (2008).
75. Rouse MS, Steckelberg JM, Patel R. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection. Diagn. Microbiol. Infect. Dis. 58(3), 363-365 (2007). (Pubitemid 47017650)
76. Zhanel GG, Voth D, Nichol K, Karlowsky JA, Noreddin AM, Hoban DJ. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. J. Antimicrob. Chemother. 64(2), 364-369 (2009).
77. Hellmark B, Unemo M, Nilsdotter-Augustinsson A, Soderquist B. Antibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections with special focus on rifampicin and variability of the rpoB gene. Clin. Microbiol. Infect. 15(3), 238-244 (2009).
78. Kosowska K, Hoellman DB, Lin G et al. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49(5), 1932-1942 (2005).
79. Jones ME. In-vitro profile of a new β-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 13(Suppl. 2), 17-24 (2007).
80. von Eiff C, Friedrich AW, Becker K, Peters G. Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes. Antimicrob. Agents Chemother. 49(10), 4372-4374 (2005). (Pubitemid 41400991)
81. Hilliard J, Foleno BD, Wira E, Melton J, Flamm RK, Bush K. Effects of ceftobiprole and vancomycin combinations in vitro and in vivo against Staphylococcus aureus. Presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America 46th annual meeting. Washington DC, USA, 25-28 October 2008.
82. Arias CA, Singh KV, Panesso D, Murray BE. Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model. J. Antimicrob. Chemother. 60(3), 594-598 (2007). (Pubitemid 47299874)
83. Goldstein EJC, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Antimicrob. Agents Chemother. 50(11), 3959-3962 (2006).
84. Pankuch GA, Appelbaum PC. Postantibiotic effect of ceftobiprole against 12 Gram-positive organisms. Antimicrob. Agents Chemother. 50(11), 3956-3958 (2006).
85. Craig WA, Andes DR. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob. Agents Chemother. 52(10), 3492-3496 (2008).
86. Livermore DM, Hope R, Brick G, Lillie M, Reynolds R. Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-2006. J. Antimicrob. Chemother. 62(Suppl. 2). ii55-ii63 (2008).
87. Livermore DM, Hope R, Brick G, Lillie M, Reynolds R. Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-2006. J. Antimicrob. Chemother. 62(Suppl. 2), ii41-ii54 (2008).
88. Issa NC, Rouse MS, Piper KE, Wilson WR, Steckelberg JM, Patel R. In vitro activity of BAL9141 against clinical isolates of Gram-negative bacteria. Diagn. Microbiol. Infect. Dis. 48(1), 73-75 (2004). (Pubitemid 38167504)
89. Pillar CM, Aranza MK, Shah D, Sahm DF. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent Gram-positive and Gram-negative isolates of European origin. J. Antimicrob. Chemother. 61(3), 595-602 (2008). (Pubitemid 351321133)
90. Walkty A, Decorby M, Nichol K, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU Study. J. Antimicrob. Chemother. 62(1), 206-208 (2008). (Pubitemid 351865899)
91. Zbinden R, Pünter V, von Graevenitz A. In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against Gram-negative nonfermenters. Antimicrob. Agents Chemother. 46(3), 871-874 (2002). (Pubitemid 34157678)
92. Thamlikitkul V, Trakulsomboon S. In vitro activity of ceftobiprole against Burkholderia pseudomallei. J. Antimicrob. Chemother. 61(2), 460-461 (2008).
93. Marti S, Sanchez-Cespedes J, Espinal P, Vila J. In vitro activity of ceftobiprole against Acinetobacter baumannii clinical isolates. Int. J. Antimicrob. Agents 34, 265-267 (2009).
94. Queenan AM, Shang W, Kania M, Page MGP, Bush K. Interactions of ceftobiprole with β-lactamases from molecular classes A to D. Antimicrob. Agents Chemother. 51(9), 3089-3095 (2007). (Pubitemid 350067513)
95. Amsler KM, Davies TA, Shang W, Jacobs MR, Bush K. In vitro activity of ceftobiprole against pathogens from two Phase 3 clinical trials of complicated skin and skin structure infections. Antimicrob. Agents Chemother. 52(9), 3418-3423 (2008).
96. Ednie L, Shapiro S, Appelbaum PC. Antianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin. Diagn. Microbiol. Infect. Dis. 58(1), 133-136 (2007). (Pubitemid 46694260)
97. Wootton M, Bowker KE, Holt HA, MacGowan AP. BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials. J. Antimicrob. Chemother. 49(3), 535-539 (2002). (Pubitemid 34223676)
98. Azoulay-Dupuis E, Bedos JP, Mohler J, Schmitt-Hoffmann A, Schleimer M, Shapiro S. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrob. Agents Chemother. 48(4), 1105-1111 (2004). (Pubitemid 38405461)
99. Chambers HF. Ceftobiprole: in-vivo profile of a bactericidal cephalosporin. Clin. Microbiol. Infect. 12(Suppl. 2), 17-22 (2006).
100. Entenza JM, Hohl P, Heinze-Krauss I, Glauser MP, Moreillon P. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. 46(1), 171-177 (2002). (Pubitemid 34031620)
101. Laohavaleeson S, Tessier PR, Nicolau DP. Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains. Antimicrob. Agents Chemother. 52(7), 2389-2394 (2008). (Pubitemid 351915667)
102. Rouse MS, Hein MM, Anguita-Alonso P, Steckelberg JM, Patel R. Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia. Diagn. Microbiol. Infect. Dis. 55(4), 333-336 (2006). (Pubitemid 44128728)
103. Vaudaux P, Gjinovci A, Bento M, Li D, Schrenzel J, Lew DP. Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49(9), 3789-3793 (2005). (Pubitemid 41233033)
104. Yin L-Y, Calhoun JH, Thomas JK, Shapiro S, Schmitt-Hoffmann A. Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52(5), 1618-1622 (2008). (Pubitemid 351614651)
105. Barbour A, Schmidt S, Sabarinath SN et al. Soft tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis. Antimicrob. Agents Chemother. 53(7), 2773-2776 (2009).
106. Kimko H, Murthy B, Xu X, Nandy P, Strauss R, Noel G. Population pharmacokinetic ana lysis of ceftobiprole for treatment of complicated skin and skin structure infections. Antimicrob. Agents Chemother. 53(3), 1228-1230 (2009).
107. Murthy B, Skee D, Vaccaro N et al. An open-label pharmakinetic study of ceftobiprole in healthy subjects and subjects with end-stage renal disease receiving hemodialysis. Presented at: 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington DC, USA, 25-28 October 2008 (Poster A-1896).
108. Chan P, Bishop A, Kupiec TC et al. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am. J. Health Syst. Pharm. 65(16), 1545-1551 (2008).
109. Lodise TP, Patel N, Renaud-Mutart A, Gorodecky E, Fritsche TR, Jones RN. Pharmacokinetic and pharmacodynamic profile of ceftobiprole. Diagn. Microbiol. Infect. Dis. 61(1), 96-102 (2008).
110. Lodise TP, Pypstra R, Kahn JB et al. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic ana lysis of 150 subjects. Antimicrob. Agents Chemother. 51(7), 2378-2387 (2007). (Pubitemid 47047314)
111. Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by Gram-positive bacteria. Antimicrob. Agents Chemother. 52(1), 37-44 (2008). •• One of ceftobiprole's Phase III clinical trials.
112. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin. Infect. Dis. 46(5), 647-655 (2008). •• One of ceftobiprole's Phase III clinical trials. (Pubitemid 351321545)
113. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement. 27(1). CLSI document M100-S17 (2007).
114. Nicholson SC, Strauss RS, Michiels B, Noel GJ. Efficacy of ceftobiprole for the treatment of severely ill patients hospitalized with community-acquired pneumonia. Presented at: ATS International Conference. Toronto, Canada, 16-21 May 2008 (Poster C-17).
115. Noel GJ, Strauss R, Shah A, Bagchi P, Group BS. Ceftobiprole versus ceftazidime combined with linezolid for treatment of patients with nosocomial pneumonia. Presented at: 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington DC, USA, 25-28 October 2008 (Poster K-486).
116. Hope R, Livermore DM, Brick G, Lillie M, Reynolds R. Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-2006. J. Antimicrob. Chemother. 62(Suppl. 2), ii65-ii74 (2008).
117. Arias CA, Singh KV, Panesso D, Murray BE. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including β-lactamase- producing and vancomycin-resistant isolates. Antimicrob. Agents Chemother. 51(6), 2043-2047 (2007). (Pubitemid 46903092)
118. Press release: Ceftobiprole, a new anti-MRSA broad-spectrum antibiotic, receives its first marketing authorization by Health Canada www.hbmpartners.com/ assets/pdf/pressemitteilungen/2008/20080630-Ceftobiprole-Receives-its-First- Marketing-Authorization-by-Health-Canada.pdf
119. Press release: Ceftobiprole, a new anti-MRSA broad-spectrum antibiotic, receives approval by Swissmedic http://hugin. info/134390/R/1269270/280612.pdf
120. Basilea Pharmaceutica: Ceftobripole www.basilea.com/development/ ceftobiprole
121. Basilea Pharmaceutica: Basilea confirms its press release of February 24, 2009 www.basilea.com/News-and-Media/Basilea-confirms-its-press-release-of- February-24-2009/240
122. Basilea Pharmaceutica files claims against Johnson&Johnson over its handling of ceftobiprole (ZEFTERA™/Zevtera™) clinical studies www.basilea.com/News-and-Media/Basilea-Pharmaceutica-files-claims-against- JohnsonJohnson-over-its-handling-of-ceftobiprole-ZEFTERA-Zevtera-clinical- studies/238